Better Information, Better Decisions
New advanced prostate cancer tests lead to better informed treatment plans.
Get more insights about prostate cancer, whether you are assessing your risk beyond the PSA test or treating prostate cancer.
Use state-of-the-art biomarker tests to inform treatment recommendations for your patients.
What are new advanced prostate cancer tests in 2023?
Prostate cancer biomarker tests provide more insights about prostate cancer risk beyond the traditional PSA test.
New advanced prostate cancer tests in 2023 can alleviate worry and provide more information about prostate cancer treatment. A high PSA test doesn’t always tell the entire story or warrant a biopsy right away.
Advanced prostate cancer tests are also known as prostate cancer markers (PCMs) or prostate biomarker tests. There are different tests based on where someone is on their prostate cancer journey. With the right test at the right time, patients and their healthcare providers can better identify risk, prognosis, treatment and next steps. Advanced prostate cancer tests in 2023 are non-invasive and can lead to better plans of action for tackling prostate cancer.
Stay up-to-date with the latest prostate cancer news with the links below.
International Prostate Cancer Conference
Healthcare providers who screen or treat men for prostate cancer shouldn't miss the 33rd Annual International Prostate Cancer Update, Jan. 22-25, in Vail, Colorado. Groundbreaking studies and practice implications will be presented.
Learn the PCMs Right for You
Take this interactive quiz to learn which advanced prostate cancer biomarker tests are right for you, whether you are deciding if you need to be screened or you want more insights into your diagnosis and treatment plan.
New Prostate Cancer Marker Identified
Swedish researchers have identified specific proteins in the transforming growth factor beta (TGF-β) signalling pathway, which is a significant path that affects how prostate cancer cells grow and spread. The discovery may make it easier to identify men who are at risk of developing aggressive and life-threatening prostate cancer.